Nov 2019

GML is currently working with the National Center for Advancing Translational Sciences (NCATS) for its RUX anti-inflammatory product and is modifying its NCI Experimental Therapeutics (NExT) application for resubmission of its chemotherapeutic Toroglobulin.

Product Development News